Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Antimicrob Agents ; 59(3): 106538, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35091055

ABSTRACT

Multinational surveillance programmes for methicillin-resistant Staphylococcus aureus (MRSA) are dependent on national structures for data collection. This study aimed to capture the diversity of national MRSA surveillance programmes and to propose a framework for harmonisation of MRSA surveillance. The International Society of Antimicrobial Chemotherapy (ISAC) MRSA Working Group conducted a structured survey on MRSA surveillance programmes and organised a webinar to discuss the programmes' strengths and challenges as well as guidelines for harmonisation. Completed surveys represented 24 MRSA surveillance programmes in 16 countries. Several countries reported separate epidemiological and microbiological surveillance. Informing clinicians and national policy-makers were the most common purposes of surveillance. Surveillance of bloodstream infections (BSIs) was present in all programmes. Other invasive infections were often included. Three countries reported active surveillance of MRSA carriage. Methodology and reporting of antimicrobial susceptibility, virulence factors, molecular genotyping and epidemiological metadata varied greatly. Current MRSA surveillance programmes rely upon heterogeneous data collection systems, which hampers international epidemiological monitoring and research. To harmonise MRSA surveillance, we suggest improving the integration of microbiological and epidemiological data, implementation of central biobanks for MRSA isolate collection, and inclusion of a representative sample of skin and soft-tissue infection cases in addition to all BSI cases.


Subject(s)
Methicillin-Resistant Staphylococcus aureus , Soft Tissue Infections , Staphylococcal Infections , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Epidemiological Monitoring , Humans , Soft Tissue Infections/drug therapy , Staphylococcal Infections/drug therapy
2.
Int J Mol Sci ; 19(7)2018 Jul 03.
Article in English | MEDLINE | ID: mdl-29970871

ABSTRACT

Human adipose-derived stromal cells (hASCs) are widely known for their immunomodulatory and anti-inflammatory properties. This study proposes a method to protect cells during and after their injection by encapsulation in a hydrogel using a droplet millifluidics technique. A biocompatible, self-hardening biomaterial composed of silanized-hydroxypropylmethylcellulose (Si-HPMC) hydrogel was used and dispersed in an oil continuous phase. Spherical particles with a mean diameter of 200 µm could be obtained in a reproducible manner. The viability of the encapsulated hASCs in the Si-HPMC particles was 70% after 14 days in vitro, confirming that the Si-HPMC particles supported the diffusion of nutrients, vitamins, and glucose essential for survival of the encapsulated hASCs. The combination of droplet millifluidics and biomaterials is therefore a very promising method for the development of new cellular microenvironments, with the potential for applications in biomedical engineering.


Subject(s)
Hydrogels/chemistry , Mesenchymal Stem Cells/cytology , Biocompatible Materials/chemistry , Biocompatible Materials/pharmacology , Cell Differentiation/drug effects , Cells, Cultured , Humans , Hydrogels/pharmacology , Hypromellose Derivatives/chemistry , Mesenchymal Stem Cells/drug effects
3.
Stem Cells Int ; 2017: 9303598, 2017.
Article in English | MEDLINE | ID: mdl-29158741

ABSTRACT

While therapeutically interesting, the injection of MSCs suffers major limitations including cell death upon injection and a massive leakage outside the injection site. We proposed to entrap MSCs within spherical particles derived from alginate, as a control, or from silanized hydroxypropyl methylcellulose (Si-HPMC). We developed water in an oil dispersion method to produce small Si-HPMC particles with an average size of about 68 µm. We evidenced a faster diffusion of fluorescein isothiocyanate-dextran in Si-HPMC particles than in alginate ones. Human adipose-derived MSCs (hASC) were encapsulated either in alginate or in Si-HPMC, and the cellularized particles were cultured for up to 1 month. Both alginate and Si-HPMC particles supported cell survival, and the average number of encapsulated hASC per alginate and Si-HPMC particle (7102 and 5100, resp.) did not significantly change. The stimulation of encapsulated hASC with proinflammatory cytokines resulted in the production of IDO, PGE2, and HGF whose concentration was always higher when cells were encapsulated in Si-HPMC particles than in alginate ones. We have demonstrated that Si-HPMC and alginate particles support hASC viability and the maintenance of their ability to secrete therapeutic factors.

4.
Best Pract Res Clin Rheumatol ; 31(5): 730-745, 2017 10.
Article in English | MEDLINE | ID: mdl-30509417

ABSTRACT

Osteoarthritis (OA) is a degenerative and inflammatory joint disease that affects the cartilage, subchondral bone, and joint tissues. Although current drug therapies can provide a degree of symptomatic relief from pain, they fail to prevent joint damage. Mesenchymal stem/stromal cells (MSCs) have generated significant interest in terms of medical applications because they exert their therapeutic properties by secretion of bioactive factors that have potent immunomodulatory, antiapoptotic, antifibrotic, and anti-inflammatory effects. However, intra-articular injection of MSCs has major limitations including cell death upon injection and massive leakage from the injection site. Encapsulation of MSCs has therefore been developed as a way to overcome these limitations and to deliver therapeutic bioactive factors in several pathologies. In this review, we first briefly highlight the main therapeutic properties of MSCs and their applications in OA treatment. We then focus on MSC encapsulation and the current advances this strategy offers for the treatment of OA.


Subject(s)
Biocompatible Materials , Mesenchymal Stem Cell Transplantation/methods , Osteoarthritis/therapy , Humans , Injections, Intra-Articular
SELECTION OF CITATIONS
SEARCH DETAIL
...